Understanding the EORTC QLQ-BM22, the module for patients with bone metastases

Area of Science:

• Oncology
• Palliative Care
• Quality of Life Research

Background:

• Bone metastases are a common cancer complication, with improved patient survival necessitating better QoL monitoring.
• Existing QoL instruments are insufficient for assessing the specific needs of patients with bone metastases.
• There is a critical need for validated tools to monitor treatment benefits and side effects, focusing on patient QoL.

Purpose of the Study:

• To develop and validate a comprehensive, bone metastases-specific QoL instrument.
• To introduce the European Organization for Research and Treatment of Cancer (EORTC) QoL Group Bone Metastases Module (QLQ-BM22).
• To facilitate international validation and use of the QLQ-BM22 in clinical practice and trials.

Main Methods:

• Development of the EORTC QLQ-BM22 following EORTC Quality of Life Group (QLG) guidelines.
• Phase IV testing of the QLQ-BM22 alongside the EORTC QLQ-C15-PAL palliative core questionnaire.
• International validation to ensure broad applicability and reliability.

Main Results:

• The EORTC QLQ-BM22 has been developed as a dedicated instrument for bone metastases QoL assessment.
• Phase IV testing will be conducted concurrently with the QLQ-C15-PAL to minimize patient burden.
• International validation is planned to support its use in diverse palliative care settings.

Conclusions:

• The EORTC QLQ-BM22 provides a much-needed, validated tool for measuring QoL in bone metastases patients.
• This module will enable consistent QoL outcome measurement across clinical trials and daily practice.
• It will support healthcare professionals in patient care, treatment selection, and cost-effectiveness assessments.